Letermovir
Who holds supplier records for Letermovir? 10 organisations hold a current record for Letermovir: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: China (5) and India (4); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Letermovir: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/letermovir
Reading the evidence
- 10 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 5 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Letermovir expires 28 Feb 2033. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (10)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Letermovir. Country is the organisation's recorded country, not necessarily the manufacturing site.
- BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITEDIndiaActive DMF 43302 · latest filing Dec 2025
- HONOUR LAB LTDIndia Company GMP cert on recordActive DMF 41441 · latest filing Jun 2025
- LUPIN MANUFACTURING SOLUTIONS LTDActive DMF 35981 · latest filing Jun 2021
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia Company GMP cert on recordActive DMF 43953 · latest filing Mar 2026
- NANTONG JINGHUA PHARMACEUTICAL CO LTDChinaActive DMF 41229 · latest filing Jan 2025
- Shandong Chenghui Shuangda Pharmaceutical Co., LtdChinaActive DMF 44048 · latest filing Apr 2026
- Shanghai Desano Chemical Pharmaceutical Co., LtdChinaActive DMF 40787 · latest filing Nov 2024
- Zhejiang Charioteer Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 39852 · latest filing Apr 2024
- Zhejiang Hisun Pharmaceutical Co., Ltd.China Company GMP cert on recordActive DMF 42309 · latest filing Jul 2025
- Zydus Lifesciences LimitedIndia Company GMP cert on recordActive DMF 36024 · latest filing Jun 2021
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (6 listed products contain Letermovir). The latest listed patent expires 28 Feb 2033. The latest listed exclusivity runs to 30 Aug 2031. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Letermovir is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1241951).
Chemical identity
- IUPAC name
- 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid
- Canonical SMILES
- COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
- InChIKey
- FWYSMLBETOMXAG-QHCPKHFHSA-N
- Synonyms
- AIC 246, AIC-246, AIC246, Letermovir, MK-8228, Prevymis, letermovirum, RefChem:57199, J05AX18, Letermovir [INN], Letermovir [USAN:INN], Prevymis (TN)
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Cytomegalovirus DNA Terminase Complex Inhibitor
- Mechanism of action
- Cytochrome P450 2C19 Inducers; Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2C9 Inducers; Cytochrome P450 3A Inhibitors; DNA Terminase Complex Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Letermovir?
10 organisations hold an active US FDA Type II Drug Master File or a CEP for Letermovir: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), HONOUR LAB LTD (India), LUPIN MANUFACTURING SOLUTIONS LTD, MSN LIFE SCIENCES PRIVATE LIMITED (India), NANTONG JINGHUA PHARMACEUTICAL CO LTD (China), Shandong Chenghui Shuangda Pharmaceutical Co., Ltd (China), Shanghai Desano Chemical Pharmaceutical Co., Ltd (China) and Zhejiang Charioteer Pharmaceutical Co., Ltd. (China), and 2 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Letermovir Drug Master Files are active?
BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 43302), HONOUR LAB LTD (DMF 41441), LUPIN MANUFACTURING SOLUTIONS LTD (DMF 35981), MSN LIFE SCIENCES PRIVATE LIMITED (DMF 43953), NANTONG JINGHUA PHARMACEUTICAL CO LTD (DMF 41229), Shandong Chenghui Shuangda Pharmaceutical Co., Ltd (DMF 44048), Shanghai Desano Chemical Pharmaceutical Co., Ltd (DMF 40787) and Zhejiang Charioteer Pharmaceutical Co., Ltd. (DMF 39852) and 2 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Letermovir?
Yes. The latest patent listed for an approved US product containing Letermovir expires 28 Feb 2033, across 6 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Letermovir supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Letermovir?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.